Search

Your search keyword '"Smolej, Lukas"' showing total 215 results
Start Over Author "Smolej, Lukas"
215 results on '"Smolej, Lukas"'

1. Modern Approach to Prognostication and Therapy of Chronic Lymphocytic Leukemia

Author

Smolej, Lukáš, Rezaei, Nima, Series Editor, Aguiar, Rodrigo, Editorial Board Member, Ahmed, Atif A., Editorial Board Member, Ambrosio, Maria R., Editorial Board Member, Artac, Mehmet, Editorial Board Member, Augustine, Tanya N., Editorial Board Member, Bambauer, Rolf, Editorial Board Member, Bhat, Ajaz Ahmad, Editorial Board Member, Bertolaccini, Luca, Editorial Board Member, Bianchini, Chiara, Editorial Board Member, Cavic, Milena, Editorial Board Member, Chakrabarti, Sakti, Editorial Board Member, Cho, William C. S., Editorial Board Member, Czarnecka, Anna M., Editorial Board Member, Domingues, Cátia, Editorial Board Member, Eşkazan, A. Emre, Editorial Board Member, Fares, Jawad, Editorial Board Member, Fonseca Alves, Carlos E., Editorial Board Member, Fru, Pascaline, Editorial Board Member, Da Gama Duarte, Jessica, Editorial Board Member, García, Mónica C., Editorial Board Member, Gener, Melissa A.H., Editorial Board Member, Estrada Guadarrama, José Antonio, Editorial Board Member, Hargadon, Kristian M., Editorial Board Member, Holvoet, Paul, Editorial Board Member, Jurisic, Vladimir, Editorial Board Member, Kabir, Yearul, Editorial Board Member, Katsila, Theodora, Editorial Board Member, Kleeff, Jorg, Editorial Board Member, Liang, Chao, Editorial Board Member, Tan, Mei Lan, Editorial Board Member, Li, Weijie, Editorial Board Member, Prado López, Sonia, Editorial Board Member, Macha, Muzafar A., Editorial Board Member, Malara, Natalia, Editorial Board Member, Orhan, Adile, Editorial Board Member, Prado-Garcia, Heriberto, Editorial Board Member, Pérez-Velázquez, Judith, Editorial Board Member, Rashed, Wafaa M., Editorial Board Member, Sanguedolce, Francesca, Editorial Board Member, Sorrentino, Rosalinda, Editorial Board Member, Shubina, Irina Zh., Editorial Board Member, de Araujo, Heloisa Sobreiro Selistre, Editorial Board Member, Torres-Suárez, Ana Isabel, Editorial Board Member, Włodarczyk, Jakub, Editorial Board Member, Yeong, Joe Poh Sheng, Editorial Board Member, Toscano, Marta A., Editorial Board Member, Wong, Tak-Wah, Editorial Board Member, Yin, Jun, Editorial Board Member, Yu, Bin, Editorial Board Member, and Hamdy, Nadia M., Editorial Board Member

Published
2024
Full Text
View/download PDF

2. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

Author

Chatzikonstantinou, Thomas, Scarfò, Lydia, Karakatsoulis, Georgios, Minga, Eva, Chamou, Dimitra, Iacoboni, Gloria, Kotaskova, Jana, Demosthenous, Christos, Smolej, Lukas, Mulligan, Stephen, Alcoceba, Miguel, Al-Shemari, Salem, Aurran-Schleinitz, Thérèse, Bacchiarri, Francesca, Bellido, Mar, Bijou, Fontanet, Calleja, Anne, Medina, Angeles, Khan, Mehreen Ali, Cassin, Ramona, Chatzileontiadou, Sofia, Collado, Rosa, Christian, Amy, Davis, Zadie, Dimou, Maria, Donaldson, David, Santos, Gimena Dos, Dreta, Barbara, Efstathopoulou, Maria, El-Ashwah, Shaimaa, Enrico, Alicia, Fresa, Alberto, Galimberti, Sara, Galitzia, Andrea, García-Serra, Rocío, Gimeno, Eva, González-Gascón-y-Marín, Isabel, Gozzetti, Alessandro, Guarente, Valerio, Guieze, Romain, Gogia, Ajay, Gupta, Ritu, Harrop, Sean, Hatzimichael, Eleftheria, Herishanu, Yair, Hernández-Rivas, José-Ángel, Inchiappa, Luca, Jaksic, Ozren, Janssen, Susanne, Kalicińska, Elżbieta, Laribi, Kamel, Karakus, Volkan, Kater, Arnon P., Kho, Bonnie, Kislova, Maria, Konstantinou, Eliana, Koren-Michowitz, Maya, Kotsianidis, Ioannis, Kreitman, Robert J., Labrador, Jorge, Lad, Deepesh, Levin, Mark-David, Levy, Ilana, Longval, Thomas, Lopez-Garcia, Alberto, Marquet, Juan, Martin-Rodríguez, Lucia, Maynadié, Marc, Maslejova, Stanislava, Mayor-Bastida, Carlota, Mihaljevic, Biljana, Milosevic, Ivana, Miras, Fatima, Moia, Riccardo, Morawska, Marta, Murru, Roberta, Nath, Uttam Kumar, Navarro-Bailón, Almudena, Oliveira, Ana C., Olivieri, Jacopo, Oscier, David, Panovska-Stavridis, Irina, Papaioannou, Maria, Papajík, Tomas, Kubova, Zuzana, Phumphukhieo, Punyarat, Pierie, Cheyenne, Puiggros, Anna, Rani, Lata, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Daniel de Deus Santos, Marcos, Schipani, Mattia, Schiwitza, Annett, Shen, Yandong, Simkovic, Martin, Smirnova, Svetlana, Abdelrahman Soliman, Dina Sameh, Spacek, Martin, Tadmor, Tamar, Tomic, Kristina, Tse, Eric, Vassilakopoulos, Theodoros, Visentin, Andrea, Vitale, Candida, von Tresckow, Julia, Vrachiolias, George, Vukovic, Vojin, Walewska, Renata, Wasik-Szczepanek, Ewa, Xu, Zhenshu, Yagci, Munci, Yañez, Lucrecia, Yassin, Mohamed, Zuchnicka, Jana, Angelopoulou, Maria, Antic, Darko, Biderman, Bella, Catherwood, Mark, Claus, Rainer, Coscia, Marta, Cuneo, Antonio, Demirkan, Fatih, Espinet, Blanca, Gaidano, Gianluca, Kalashnikova, Olga B., Laurenti, Luca, Nikitin, Eugene, Pangalis, Gerassimos A., Panagiotidis, Panagiotis, Popov, Viola Maria, Pospisilova, Sarka, Sportoletti, Paolo, Stavroyianni, Niki, Tam, Constantine, Trentin, Livio, Chatzidimitriou, Anastasia, Bosch, Francesc, Doubek, Michael, Ghia, Paolo, and Stamatopoulos, Kostas

Published
2023
Full Text
View/download PDF

4. Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia

Author

Salles, Gilles, Bachy, Emmanuel, Smolej, Lukas, Simkovic, Martin, Baseggio, Lucile, Panovska, Anna, Besson, Hervé, Healy, Nollaig, Garside, Jamie, Iraqi, Wafae, Diels, Joris, Pick-Lauer, Corinna, Spacek, Martin, Urbanova, Renata, Lysak, Daniel, Hermans, Ruben, Lundbom, Jessica, Callet-Bauchu, Evelyne, and Doubek, Michael

Published
2019
Full Text
View/download PDF

5. S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY.

Author

Chatzikonstantinou, Thomas, primary, Scarfò, Lydia, additional, Karakatsoulis, Georgios, additional, Minga, Eva, additional, Chamou, Dimitra, additional, Iacoboni, Gloria, additional, Kotaskova, Jana, additional, Demosthenous, Christos, additional, Alcoceba, Miguel, additional, Al-Shemari, Salem, additional, Aurran-Schleinitz, Thérèse, additional, Bacchiarri, Francesca, additional, Bellido, Mar, additional, Bijou, Fontanet, additional, Calleja, Anne, additional, Medina, Angeles, additional, Khan, Mehreen Ali, additional, Cassin, Ramona, additional, Chatzileontiadou, Sofia, additional, Collado, Rosa, additional, Davis, Zadie, additional, Dimou, Maria, additional, Donaldson, David, additional, Santos, Gimena Dos, additional, Dreta, Barbara, additional, Efstathopoulou, Maria, additional, El-Ashwah, Shaimaa, additional, Enrico, Alicia, additional, Fresa, Alberto, additional, Galimberti, Sara, additional, Galitzia, Andrea, additional, García-Serra, Rocío, additional, Gimeno, Eva, additional, González-Gascón-Y-Marín, Isabel, additional, Gozzetti, Alessandro, additional, Guarente, Valerio, additional, Guieze, Romain, additional, Gogia, Ajay, additional, Gupta, Ritu, additional, Harrop, Sean, additional, Hatzimichael, Eleftheria, additional, Herishanu, Yair, additional, Hernández-Rivas, José-Ángel, additional, Inchiappa, Luca, additional, Jaksic, Ozren, additional, Janssen, Susanne, additional, Kalicińska, Elżbieta, additional, Kamel, Laribi, additional, Karakus, Volkan, additional, Kater, Arnon P, additional, Kho, Bonnie, additional, Kislova, Maria, additional, Konstantinou, Εliana, additional, Koren-Michowitz, Maya, additional, Kotsianidis, Ioannis, additional, Kreitman, Robert J, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Levin, Mark-David, additional, Levy, Ilana, additional, Longval, Thomas, additional, Lopez-Garcia, Alberto, additional, Marquet, Juan, additional, Maynadié, Marc, additional, Maslejova, Stanislava, additional, Mayor-Bastida, Carlota, additional, Mihaljevic, Biljana, additional, Milosevic, Ivana, additional, Miras, Fatima, additional, Moia, Riccardo, additional, Morawska, Marta, additional, Murru, Roberta, additional, Nath, Uttam Kumar, additional, Navarro-Bailón, Almudena, additional, Oliveira, Ana C., additional, Olivieri, Jacopo, additional, Oscier, David, additional, Panovska-Stavridis, Irina, additional, Papaioannou, Maria, additional, Papajík, Tomas, additional, Phumphukhieo, Punyarat, additional, Pierie, Cheyenne, additional, Puiggros, Anna, additional, Rani, Lata, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Ronson, Aharon, additional, Ruchlemer, Rosa, additional, de Deus Santos, Marcos Daniel, additional, Schipani, Mattia, additional, Schiwitza, Annett, additional, Shen, Yandong, additional, Simkovic, Martin, additional, Smirnova, Svetlana, additional, Sameh Abdelrahman Soliman, Dina, additional, Spacek, Martin, additional, Tadmor, Tamar, additional, Tomic, Kristina, additional, Tse, Eric, additional, Vassilakopoulos, Theodoros, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Tresckow, Julia von, additional, Vrachiolias, George, additional, Vukovic, Vojin, additional, Walewska, Renata, additional, Wasik-Szczepanek, Ewa, additional, Xu, Zhenshu, additional, Yagci, Munci, additional, Yañez, Lucrecia, additional, Yassin, Mohamed, additional, Zuchnicka, Jana, additional, Angelopoulou, Maria, additional, Antic, Darko, additional, Biderman, Bella, additional, Catherwood, Mark, additional, Claus, Rainer, additional, Coscia, Marta, additional, Cuneo, Antonio, additional, Demirkan, Fatih, additional, Espinet, Blanca, additional, Gaidano, Gianluca, additional, Kalashnikova, Olga, additional, Laurenti, Luca, additional, Nikitin, Eugene, additional, Pangalis, Gerassimos A., additional, Panagiotidis, Panagiotis, additional, Mulligan, Stephen, additional, Popov, Viola Maria, additional, Pospisilova, Sarka, additional, Smolej, Lukas, additional, Sportoletti, Paolo, additional, Stavroyianni, Niki, additional, Tam, Constantine, additional, Trentin, Livio, additional, Chatzidimitriou, Anastasia, additional, Bosch, Francesc, additional, Doubek, Michael, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2023
Full Text
View/download PDF

6. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

Author

Zelenetz, Andrew D, Barrientos, Jacqueline C, Brown, Jennifer R, Coiffier, Bertrand, Delgado, Julio, Egyed, Miklós, Ghia, Paolo, Illés, Árpád, Jurczak, Wojciech, Marlton, Paula, Montillo, Marco, Morschhauser, Franck, Pristupa, Alexander S, Robak, Tadeusz, Sharman, Jeff P, Simpson, David, Smolej, Lukáš, Tausch, Eugen, Adewoye, Adeboye H, Dreiling, Lyndah K, Kim, Yeonhee, Stilgenbauer, Stephan, and Hillmen, Peter

Published
2017
Full Text
View/download PDF

7. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

Author

AbbVie Pharmaceuticals, European Commission, Chatzikonstantinou, Thomas, Scarfò, Lydia, Karakatsoulis, Georgios, Minga, Eva, Chamou, Dimitra, Iacoboni, Gloria, Kotaskova, Jana, Demosthenous, Christos, Smolej, Lukas, Mulligan, Stephen, Alcoceba, Miguel, Kreitman, Robert J., Labrador, Jorge, Lad, Deepesh, Levin, Mark-David, Levy, Ilana, Longval, Thomas, López-García, Alberto, Marquet, Juan, Martín-Rodríguez, Lucía, Maynadié, Marc, Tadmor, Tamar, Maslejova, Stanislava, Mayor-Bastida, Carlota, Mihaljevic, Biljana, Milosevic, Ivana, Mirás, Fátima, Moia, Riccardo, Morawska, Marta, Murru, Roberta, Nath, Uttam Kumar, Navarro-Bailón, Almudena, Tomic, Kristina, Oliveira, Ana C., Olivieri, Jacopo, Oscier, David, Panovska-Stavridis, Irina, Papaioannou, María, Papajík, Tomás, Kubova, Zuzana, Phumphukhieo, Punyarat, Pierie, Cheyenne, Puiggros, Anna, Tse, Eric, Rani, Lata, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Daniel de Deus Santos, Marcos, Schipani, Mattia, Schiwitza, Annett, Shen, Yandong, Simkovic, Martín, Smirnova, Svetlana, Vassilakopoulos, Theodoros, Abdelrahman Soliman, Dina Sameh, Spacek, Martin, Visentin, Andrea, Vitale, Candida, von Tresckow, Julia, Vrachiolias, George, Vukovic, Vojin, Walewska, Renata, Al-Shemari, Salem, Wasik-Szczepanek, Ewa, Xu, Zhenshu, Yagci, Munci, Yañez, Lucrecia, Yassin, Mohamed, Zuchnicka, Jana, Angelopoulou, Maria, Antic, Darko, Biderman, Bella, Catherwood, Mark, Aurran-Schleinitz, Thérèse, Claus, Rainer, Coscia, Marta, Cuneo, Antonio, Demirkan, Fatih, Espinet, Blanca, Gaidano, Gianluca, Kalashnikova, Olga B., Laurenti, Luca, Nikitin, Eugene, Pangalis, Gerassimos A., Bacchiarri, Francesca, Panagiotidis, Panagiotis, Popov, Viola María, Pospisilova, Sarka, Sportoletti, Paolo, Stavroyianni, Niki, Tam, Constantine S., Trentin, Livio, Chatzidimitriou, Anastasia, Bosch, Francesc, Doubek, Michael, Bellido, Mar, Ghia, Paolo, Stamatopoulos, Kostas, Bijou, Fontanet, Calleja, Anne, Medina, Angeles, Khan, Mehreen Ali, Cassin, Ramona, Chatzileontiadou, Sofía, Collado, Rosa, Christian, Amy, Davis, Zadie, Dimou, María, Donaldson, David, Santos, Gimena Dos, Dreta, Bárbara, Efstathopoulou, María, El-Ashwah, Shaimaa, Enrico, Alicia, Fresa, Alberto, Galimberti, Sara, Galitzia, Andrea, García-Serra, Rocío, Gimeno, Eva, González-Gascón y Marín, Isabel, Gozzetti, Alessandro, Guarente, Valerio, Guieze, Romain, Gogia, Ajay, Gupta, Ritu, Harrop, Sean, Hatzimichael, Eleftheria, Herishanu, Yair, Hernández-Rivas, José Ángel, Inchiappa, Luca, Jaksic, Ozren, Janssen, Susanne, Kalicińska, Elżbieta, Kamel, Laribi, Karakus, Volkan, Kater, Arnon P., Kho, Bonnie, Kislova, María, Konstantinou, Eliana, Koren-Michowitz, Maya, Kotsianidis, Ioannis, AbbVie Pharmaceuticals, European Commission, Chatzikonstantinou, Thomas, Scarfò, Lydia, Karakatsoulis, Georgios, Minga, Eva, Chamou, Dimitra, Iacoboni, Gloria, Kotaskova, Jana, Demosthenous, Christos, Smolej, Lukas, Mulligan, Stephen, Alcoceba, Miguel, Kreitman, Robert J., Labrador, Jorge, Lad, Deepesh, Levin, Mark-David, Levy, Ilana, Longval, Thomas, López-García, Alberto, Marquet, Juan, Martín-Rodríguez, Lucía, Maynadié, Marc, Tadmor, Tamar, Maslejova, Stanislava, Mayor-Bastida, Carlota, Mihaljevic, Biljana, Milosevic, Ivana, Mirás, Fátima, Moia, Riccardo, Morawska, Marta, Murru, Roberta, Nath, Uttam Kumar, Navarro-Bailón, Almudena, Tomic, Kristina, Oliveira, Ana C., Olivieri, Jacopo, Oscier, David, Panovska-Stavridis, Irina, Papaioannou, María, Papajík, Tomás, Kubova, Zuzana, Phumphukhieo, Punyarat, Pierie, Cheyenne, Puiggros, Anna, Tse, Eric, Rani, Lata, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Daniel de Deus Santos, Marcos, Schipani, Mattia, Schiwitza, Annett, Shen, Yandong, Simkovic, Martín, Smirnova, Svetlana, Vassilakopoulos, Theodoros, Abdelrahman Soliman, Dina Sameh, Spacek, Martin, Visentin, Andrea, Vitale, Candida, von Tresckow, Julia, Vrachiolias, George, Vukovic, Vojin, Walewska, Renata, Al-Shemari, Salem, Wasik-Szczepanek, Ewa, Xu, Zhenshu, Yagci, Munci, Yañez, Lucrecia, Yassin, Mohamed, Zuchnicka, Jana, Angelopoulou, Maria, Antic, Darko, Biderman, Bella, Catherwood, Mark, Aurran-Schleinitz, Thérèse, Claus, Rainer, Coscia, Marta, Cuneo, Antonio, Demirkan, Fatih, Espinet, Blanca, Gaidano, Gianluca, Kalashnikova, Olga B., Laurenti, Luca, Nikitin, Eugene, Pangalis, Gerassimos A., Bacchiarri, Francesca, Panagiotidis, Panagiotis, Popov, Viola María, Pospisilova, Sarka, Sportoletti, Paolo, Stavroyianni, Niki, Tam, Constantine S., Trentin, Livio, Chatzidimitriou, Anastasia, Bosch, Francesc, Doubek, Michael, Bellido, Mar, Ghia, Paolo, Stamatopoulos, Kostas, Bijou, Fontanet, Calleja, Anne, Medina, Angeles, Khan, Mehreen Ali, Cassin, Ramona, Chatzileontiadou, Sofía, Collado, Rosa, Christian, Amy, Davis, Zadie, Dimou, María, Donaldson, David, Santos, Gimena Dos, Dreta, Bárbara, Efstathopoulou, María, El-Ashwah, Shaimaa, Enrico, Alicia, Fresa, Alberto, Galimberti, Sara, Galitzia, Andrea, García-Serra, Rocío, Gimeno, Eva, González-Gascón y Marín, Isabel, Gozzetti, Alessandro, Guarente, Valerio, Guieze, Romain, Gogia, Ajay, Gupta, Ritu, Harrop, Sean, Hatzimichael, Eleftheria, Herishanu, Yair, Hernández-Rivas, José Ángel, Inchiappa, Luca, Jaksic, Ozren, Janssen, Susanne, Kalicińska, Elżbieta, Kamel, Laribi, Karakus, Volkan, Kater, Arnon P., Kho, Bonnie, Kislova, María, Konstantinou, Eliana, Koren-Michowitz, Maya, and Kotsianidis, Ioannis

Abstract

[Background]: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and represents the focus of this work., [Methods]: We conducted a retrospective international multicenter study to assess the incidence of OMs and detect potential risk factors in 19,705 patients with CLL, small lymphocytic lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 and 2016. Data collection took place between October 2020 and March 2022., [Findings]: In 129,254 years of follow-up after CLL diagnosis, 3513 OMs were diagnosed (27.2 OMs/1000 person-years). The most common hematological OMs were Richter transformation, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Non-melanoma skin (NMSC) and prostate cancers were the most common solid tumors (STs). The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79–4.91; p < 0.001). STs were more frequent in males and patients with unmutated immunoglobulin heavy variable genes (OR = 1.77; 95% CI = 1.49–2.11; p < 0.001/OR = 1.89; 95% CI = 1.6–2.24; p < 0.001). CLL-directed treatment was associated with non-melanoma skin and prostate cancers (OR = 1.8; 95% CI = 1.36–2.41; p < 0.001/OR = 2.11; 95% CI = 1.12–3.97; p = 0.021). In contrast, breast cancers were more frequent in untreated patients (OR = 0.17; 95% CI = 0.08–0.33; p < 0.001). Patients with CLL and an OM had inferior overall survival (OS) than those without. AML and MDS conferred the worst OS (p < 0.001)., [Interpretation]: OMs in CLL impact on OS. Treatment for CLL increased the risk for AML/MDS, prostate cancer, and NMSC. FCR was associated with increased risk for AML/MDS.

Published
2023

8. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial

Author

Greil, Richard, Obrtlíková, Petra, Smolej, Lukáš, Kozák, Tomáš, Steurer, Michael, Andel, Johannes, Burgstaller, Sonja, Mikušková, Eva, Gercheva, Liana, Nösslinger, Thomas, Papajík, Tomáš, Ladická, Miriam, Girschikofsky, Michael, Hrubiško, Mikuláš, Jäger, Ulrich, Fridrik, Michael, Pecherstorfer, Martin, Králiková, Eva, Burcoveanu, Cristina, Spasov, Emil, Petzer, Andreas, Mihaylov, Georgi, Raynov, Julian, Oexle, Horst, Zabernigg, August, Flochová, Emília, Palášthy, Stanislav, Stehlíková, Olga, Doubek, Michael, Altenhofer, Petra, Pleyer, Lisa, Melchardt, Thomas, Klingler, Anton, Mayer, Jiří, and Egle, Alexander

Published
2016
Full Text
View/download PDF

15. Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL

Author

Chatzikonstantinou, Thomas, primary, Scarfo, Lydia, additional, Demosthenous, Christos, additional, Kotaskova, Jana, additional, Iacoboni, Gloria, additional, Minga, Evangelia, additional, Chammou, Dimitra, additional, Karakatsoulis, Georgios, additional, Albi, Elisa, additional, Alcoceba, Miguel, additional, El-Ashwah, Shaimaa, additional, Bacchiarri, Francesca, additional, Khan, Mehreen Ali, additional, Aurran, Thérèse, additional, Calleja, Anne, additional, Cassin, Ramona, additional, Chatzileontiadou, Sofia, additional, Christian, Amy, additional, Claus, Rainer, additional, Collado, Rosa, additional, De Deus Santos, Marcos Daniel, additional, Davis, Zadie, additional, Dimou, Maria, additional, Donaldson, David, additional, Dos Santos, Gimena, additional, Dreta, Barbara, additional, Efstathopoulou, Maria, additional, Enrico, Alicia, additional, Fresa, Alberto, additional, Galimberti, Sara, additional, García-Serra, Rocío, additional, González-Gascón Y Marín, Isabel, additional, Gozzetti, Alessandro, additional, Guarente, Valerio, additional, Harrop, Sean, additional, Hatzimichael, Eleftheria, additional, Herishanu, Yair, additional, Inchiappa, Luca, additional, Iskas, Michalis, additional, Jaksic, Ozren, additional, Janssen, Susanne R., additional, Kalicinska, Elzbieta, additional, Karakus, Volkan, additional, Kater, Arnon P., additional, Kho, Bonnie, additional, Konstantinou, Iliana, additional, Longval, Thomas, additional, Koren-Michowitz, Maya, additional, Kotsianidis, Ioannis, additional, Kreitman, Robert J., additional, Nath, Uttam Kumar, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laribi, Kamel, additional, Levy, Ilana, additional, Lopez-Garcia, Alberto, additional, Marquet Palomanes, Juan, additional, Maslejova, Stanislava, additional, Mayor-Bastida, Carlota, additional, Merabet, Fatiha, additional, Mihaljevic, Biljana, additional, Milosevic, Ivana, additional, Miras, Fatima, additional, Moia, Riccardo, additional, Morawska, Marta, additional, Navarro-Bailón, Almudena, additional, Oscier, David, additional, Olivieri, Jacopo, additional, Papajík, Tomáš, additional, Papaioannou, Maria, additional, Pierie, Cheyenne, additional, Puiggros, Anna, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Schiattone, Luana, additional, Sevindik, Omur Gokmen, additional, Shen, Yandong, additional, Šimkovič, Martin, additional, Smirnova, Svetlana, additional, Soliman, Dina Sameh, additional, Špaček, Martin, additional, Schiwitza, Annett, additional, Tadmor, Tamar, additional, Tourjeman, Liat, additional, Tse, Eric, additional, Visentin, Andrea, additional, Tomic, Kristina, additional, Van Gelder, Michel, additional, Vassilakopoulos, Theodoros P., additional, Vitale, Candida, additional, Vrachiolias, George, additional, Vukovic, Vojin, additional, Xu, Zhenshu, additional, Yáñez, Lucrecia, additional, Yagci, Munci, additional, Yassin, Mohamed A, additional, Zuchnicka, Jana, additional, Angelopoulou, Maria K., additional, Antic, Darko, additional, Biderman, Bella V., additional, Catherwood, Mark, additional, Coscia, Marta, additional, Cuneo, Antonio, additional, Demirkan, Fatih, additional, Espinet, Blanca, additional, Gaidano, Gianluca, additional, Guièze, Romain, additional, Kalashnikova, Olga, additional, Laurenti, Luca, additional, Mulligan, Stephen, additional, Murru, Roberta, additional, Nikitin, Eugene A., additional, Panayiotidis, Panayiotis, additional, Pangalis, Gerasimos, additional, Panovska, Irina, additional, Popov, Viola Maria, additional, Pospíšilová, Šárka, additional, Smolej, Lukas, additional, Sportoletti, Paolo, additional, Stavroyianni, Niki, additional, Tam, Constantine S., additional, Trentin, Livio, additional, Trněný, Marek, additional, Bosch Albareda, Francesc, additional, Doubek, Michael, additional, Chatzidimitriou, Anastasia, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2021
Full Text
View/download PDF

16. Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study

Author

Doubek, Michael, Brychtova, Yvona, Panovska, Anna, Sebejova, Ludmila, Stehlikova, Olga, Chovancova, Jana, Malcikova, Jitka, Smardova, Jana, Plevova, Karla, Volfova, Pavlina, Trbusek, Martin, Mraz, Marek, Bakesova, Denisa, Trizuljak, Jakub, Hadrabova, Marketa, Obrtlikova, Petra, Karban, Josef, Smolej, Lukas, Oltova, Alexandra, Jelinkova, Eva, Pospisilova, Sarka, and Mayer, Jiri

Published
2015
Full Text
View/download PDF

17. Second Line Treatment with Bruton Tyrosine Kinase Inhibitor (BTKi) or Bcl-2 Inhibitor (Bcl-2i) in Patients with Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Czech Study Group for CLL (CSCLL)

Author

Mihalyova, Jana, Panovska, Anna, Simkovic, Martin, Turcsanyi, Peter, Spacek, Martin, Brejcha, Martin, Lysak, Daniel, Mocikova, Heidi, Pavlova, Sarka, Chrapava, Marika, Zuchnicka, Jana, Brychtova, Yvona, Vodarek, Pavel, Urbanova, Renata, Likarova, Tereza, Malcikova, Jitka, Jurkova, Tereza, Lancova, Klara, Bezdekova, Lucie, Papajik, Tomas, Baranova, Jana, Arpas, Tomas, Pospisilova, Sarka, Smolej, Lukas, and Doubek, Michael

Published
2023
Full Text
View/download PDF

20. Profiling of biological and environmental risk factors in immunogenetic subgroups of chronic lymphocytic leukemia - Czech national study

Author

Stranska, Kamila, primary, Plevova, Karla, additional, Skuhrova Francova, Hana, additional, Skabrahova, Hana, additional, von Jagwitz-Biegnitz, Magdalena, additional, Radova, Lenka, additional, Panovska, Anna, additional, Hrobkova, Stanislava, additional, Brychtova, Yvona, additional, Urbanova, Renata, additional, Smolej, Lukas, additional, Simkovic, Martin, additional, Zuchnicka, Jana, additional, Mohammadova, Lekaa, additional, Spacek, Martin, additional, Mayer, Jiri, additional, Pospisilova, Sarka, additional, and Doubek, Michael, additional

Published
2020
Full Text
View/download PDF

24. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study

Author

Cuneo, Antonio, Follows, George, Rigolin, Gian Matteo, Piciocchi, Alfonso, Tedeschi, Alessandra, Trentin, Livio, Perez, Angeles Medina, Coscia, Marta, Laurenti, Luca, Musuraca, Gerardo, Farina, Lucia, Delgado, Alfredo Rivas, Orlandi, Ester Maria, Galieni, Piero, Mauro, Francesca Romana, Visco, Carlo, Amendola, Angela, Billio, Atto, Marasca, Roberto, Chiarenza, Annalisa, Meneghini, Vittorio, Ilariucci, Fiorella, Marchetti, Monia, Molica, Stefano, Re, Francesca, Gaidano, Gianluca, Gonzalez, Marcos, Forconi, Francesco, Ciolli, Stefania, Cortelezzi, Agostino, Montillo, Marco, Smolej, Lukas, Schuh, Anna, Eyre, Toby A, Kennedy, Ben, Bowles, Kris M, Vignetti, Marco, de la Serna, Javier, Moreno, Carol, Foà, Robin, Ghia, Paolo, GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum, Cuneo, Antonio, Follows, George, Rigolin, Gian Matteo, Piciocchi, Alfonso, Tedeschi, Alessandra, Trentin, Livio, Perez, Angeles Medina, Coscia, Marta, Laurenti, Luca, Musuraca, Gerardo, Farina, Lucia, Delgado, Alfredo Riva, Orlandi, Ester Maria, Galieni, Piero, Mauro, Francesca Romana, Visco, Carlo, Amendola, Angela, Billio, Atto, Marasca, Roberto, Chiarenza, Annalisa, Meneghini, Vittorio, Ilariucci, Fiorella, Marchetti, Monia, Molica, Stefano, Re, Francesca, Gaidano, Gianluca, Gonzalez, Marco, Forconi, Francesco, Ciolli, Stefania, Cortelezzi, Agostino, Montillo, Marco, Smolej, Luka, Schuh, Anna, Eyre, Toby A., Kennedy, Ben, Bowles, Kris M., Vignetti, Marco, De La Serna, Javier, Moreno, Carol, Foà, Robin, and Ghia, Paolo

Subjects
Oncology, Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study, Salvage therapy, chemistry.chemical_compound, rituximab, 0302 clinical medicine, Piperidines, Antineoplastic Combined Chemotherapy Protocols, Bendamustine Hydrochloride, Aged, 80 and over, education.field_of_study, clinical trial, Hematology, Middle Aged, Prognosis, Fludarabine, Treatment Outcome, Italy, 030220 oncology & carcinogenesis, Ibrutinib, Bendamustine, Retreatment, Rituxima, Rituximab, medicine.drug, Chronic Lymphocytic Leukemia, bendamustine, ibrutinib, Adult, medicine.medical_specialty, Population, NO, 03 medical and health sciences, Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, Chemoimmunotherapy, CLL, Bendamustine, Rituxima, prognosis, Hematology, Internal medicine, medicine, Biomarkers, Tumor, Humans, Progression-free survival, education, Aged, Salvage Therapy, business.industry, Adenine, ERIC and UK CLL FORUM study, Leukemia, Lymphocytic, Chronic, B-Cell, Survival Analysis, United Kingdom, Regimen, Pyrimidines, chemistry, chronic lymphocytic leukemia, Pyrazoles, prognosis, business, CLL, 030215 immunology
Abstract

We performed an observational study on the efficacy of bendamustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS) was 25 months. The presence of del (17p), unmutated IGHV and advanced stage were associated with a shorter PFS at multivariate analysis. The median time-to-next treatment was 31.3 months. Front-line treatment with a chemoimmunotherapy regimen was the only predictive factor for a shorter time to next treatment at multivariate analysis. The median overall survival (OS) was 74.5 months. Advanced disease stage (i.e. Rai stage III-IV or Binet stage C) and resistant disease were the only parameters significantly associated with a shorter OS. Grade 3-5 infections were recorded in 6.3% of patients. A matched-adjusted indirect comparison with ibrutinib given second-line within Named Patient Programs in the United Kingdom and in Italy was carried out with OS as objective end point. When restricting the analysis to patients with intact 17p who had received chemoimmunotherapy in first line, there was no difference in OS between patients treated with ibrutinib (63% alive at 36 months) and patients treated with BR (74.4% alive at 36 months). BR is an efficacious first salvage regimen in CLL in a real-life population, including the elderly and unfit patients. BR and ibrutinib may be equally effective in terms of OS when used as first salvage treatment in patients without 17p deletion. (Registered at clinicaltrials.gov identifier: 02491398).

Published
2018

25. Role of ofatumumab (OFA) maintenance treatment in relapsed chronic lymphocytic leukemia (CLL): Final analysis of PROLONG study.

Author

Van Oers, Marinus, primary, Smolej, Lukas, additional, Petrini, Mario, additional, Offner, Fritz, additional, Grosicki, Sebastian, additional, Levin, Mark-David, additional, Davis, Jaclyn, additional, Stefanelli, Tommaso, additional, Banerjee, Hiya, additional, Hoever, Petra, additional, and Geisler, Christian, additional

Published
2018
Full Text
View/download PDF

26. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study

Author

Cuneo, Antonio, primary, Follows, George, additional, Rigolin, Gian Matteo, additional, Piciocchi, Alfonso, additional, Tedeschi, Alessandra, additional, Trentin, Livio, additional, Perez, Angeles Medina, additional, Coscia, Marta, additional, Laurenti, Luca, additional, Musuraca, Gerardo, additional, Farina, Lucia, additional, Delgado, Alfredo Rivas, additional, Orlandi, Ester Maria, additional, Galieni, Piero, additional, Mauro, Francesca Romana, additional, Visco, Carlo, additional, Amendola, Angela, additional, Billio, Atto, additional, Marasca, Roberto, additional, Chiarenza, Annalisa, additional, Meneghini, Vittorio, additional, Ilariucci, Fiorella, additional, Marchetti, Monia, additional, Molica, Stefano, additional, Re, Francesca, additional, Gaidano, Gianluca, additional, Gonzalez, Marcos, additional, Forconi, Francesco, additional, Ciolli, Stefania, additional, Cortelezzi, Agostino, additional, Montillo, Marco, additional, Smolej, Lukas, additional, Schuh, Anna, additional, Eyre, Toby A., additional, Kennedy, Ben, additional, Bowles, Kris M., additional, Vignetti, Marco, additional, de la Serna, Javier, additional, Moreno, Carol, additional, Foà, Robin, additional, and Ghia, Paolo, additional

Published
2018
Full Text
View/download PDF

28. Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

Author

Smolej, Lukas

Subjects
Pharmacogenomics and Personalized Medicine, immune system diseases, hemic and lymphatic diseases
Abstract

Lukáš Smolej 4th Department of Internal Medicine – Hematology, University Hospital Hradec Králové and Charles University in Prague, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic Abstract: Introduction of targeted agents revolutionized the treatment of chronic lymphocytic leukemia (CLL) in the past decade. Addition of chimeric monoclonal anti-CD20 antibody rituximab to chemotherapy significantly improved efficacy including overall survival (OS) in untreated fit patients; humanized anti-CD52 antibody alemtuzumab and fully human anti-CD20 antibody ofatumumab lead to improvement in refractory disease. Novel small molecule inhibitors such as ibrutinib and idelalisib demonstrated excellent activity and were very recently licensed in relapsed/refractory CLL. Obinutuzumab (GA101) is the newest monoclonal antibody approved for the treatment of CLL. This novel, glycoengineered, type II humanized anti-CD20 antibody is characterized by enhanced antibody-dependent cellular cytotoxicity and direct induction of cell death compared to type I antibodies. Combination of obinutuzumab and chlorambucil yielded significantly better OS in comparison to chlorambucil monotherapy in untreated comorbid patients. These results led to approval of obinuzutumab for the treatment of CLL. Numerous clinical trials combining obinutuzumab with other cytotoxic drugs and novel small molecules are currently under way. This review focuses on the role of obinutuzumab in the treatment of CLL. Keywords: chronic lymphocytic leukemia, anti-CD20 antibodies, chlorambucil, rituximab, ofatumumab, obinutuzumab, overall survival

Published
2014

31. A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL

Author

Flinn, Ian W., primary, Panayiotidis, Panayiotis, additional, Afanasyev, Boris, additional, Janssens, Ann, additional, Grosicki, Sebastian, additional, Homenda, Wojciech, additional, Smolej, Lukas, additional, Kuliczkowski, Kazimierz, additional, Doubek, Michael, additional, Domnikova, Natalia, additional, West, Sarah L., additional, Chang, Chai‐Ni, additional, Barker, Alison M., additional, Gupta, Ira V., additional, Wright, Oliver J., additional, and Offner, Fritz, additional

Published
2016
Full Text
View/download PDF

32. COBLL1,LPLandZAP70expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates withIGHVmutational status

Author

Plesingerova, Hana, primary, Librova, Zuzana, additional, Plevova, Karla, additional, Libra, Antonin, additional, Tichy, Boris, additional, Skuhrova Francova, Hana, additional, Vrbacky, Filip, additional, Smolej, Lukas, additional, Mayer, Jiri, additional, Bryja, Vitezslav, additional, Doubek, Michael, additional, and Pospisilova, Sarka, additional

Published
2016
Full Text
View/download PDF

33. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients

Author

Osterborg, Anders, Wierda, William G., Mayer, Jiri, Hess, Georg, Hillmen, Peter, Schetelig, Johannes, Schuh, Anna, Smolej, Lukas, Beck, Christian, Dreyfus, Brigitte, Hellman, Andrzej, Kozlowski, Piotr, Pfreundschuh, Michael, Rizzi, Rita, Spacek, Martin, Phillips, Jennifer L., Gupta, Ira V., Williams, Vanessa, Jewell, Roxanne C., Nebot, Noelia, Lisby, Steen, Dyer, Martin J. S., Osterborg, Anders, Wierda, William G., Mayer, Jiri, Hess, Georg, Hillmen, Peter, Schetelig, Johannes, Schuh, Anna, Smolej, Lukas, Beck, Christian, Dreyfus, Brigitte, Hellman, Andrzej, Kozlowski, Piotr, Pfreundschuh, Michael, Rizzi, Rita, Spacek, Martin, Phillips, Jennifer L., Gupta, Ira V., Williams, Vanessa, Jewell, Roxanne C., Nebot, Noelia, Lisby, Steen, and Dyer, Martin J. S.

Abstract

There are limited data on retreatment with monoclonal antibodies (mAb) in patients with chronic lymphocytic leukaemia (CLL). In a pivotal study, ofatumumab (human anti-CD20 mAb) monotherapy demonstrated a 47% objective response rate (ORR) in fludarabine refractory CLL patients. From this study, a subset of 29 patients who had at least stable disease and then progressed were retreated with eight weekly ofatumumab infusions (induction treatment period), followed by monthly infusions for up to 2years (maintenance treatment period). The ORR after 8weeks of induction retreatment was 45% and 24% had continued disease control after maintenance at 52weeks. Efficacy and safety of the retreated patients were compared with their initial results in the pivotal study. Response duration was 241months vs. 68months; time to next therapy was 148months vs. 123months; and progression-free survival was 74months vs. 79months (medians). Upon retreatment, 72% had infusion reactions, mostly Grade 1-2. Three patients had fatal infections. In summary, ofatumumab retreatment and maintenance therapy was feasible in patients with heavily pretreated CLL and appeared to result in more durable disease control than initial ofatumumab treatment in this subset of patients who may have a more favourable disease profile.

Published
2015
Full Text
View/download PDF

36. Single-Agent Ibrutinib Versus Real-World Treatments for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Adjusted Comparison of Resonate-2™ with Real-World Databases

Author

Salles, Gilles, Smolej, Lukas, Bachy, Emmanuel, Baseggio, Lucile, Besson, Hervé, Hermans, Ruben, Healy, Nollaig, Garside, Jamie, Iraqi, Wafae, Diels, Joris, MacDougall, Finlay, Pick-Lauer, Corinna, Spacek, Martin, Urbanova, Renata, Lysak, Daniel, Callet-Bauchu, Evelyne, and Doubek, Michael

Published
2017
Full Text
View/download PDF

38. COBLL1 , LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.

Author

Plesingerova, Hana, Librova, Zuzana, Plevova, Karla, Libra, Antonin, Tichy, Boris, Skuhrova Francova, Hana, Vrbacky, Filip, Smolej, Lukas, Mayer, Jiri, Bryja, Vitezslav, Doubek, Michael, and Pospisilova, Sarka

Subjects
CHRONIC lymphocytic leukemia, GENETIC mutation, LYMPHOCYTIC leukemia, CANCER invasiveness, LEUKEMIA, PROGNOSIS, PATIENTS
Abstract

The clinical course of chronic lymphocytic leukemia (CLL) is highly variable. Patients with unmutatedIGHV(U-CLL) usually progress rapidly, whereas patients with mutatedIGHV(M-CLL) have a more indolent disease. The expression of several genes correlates closely with theIGHVmutational status and could be used to assess prognosis in CLL. We analyzed the prognostic relevance ofCOBLL1,LPL,andZAP70gene expression, which correlated withIGHVmutational status (p < 0.0001), in 117 CLL patients and established a prognostic parameter dividing the tested cohort according to the disease aggressiveness. Our prognostic parameter was validated on an independent cohort of 161 CLL patients and achieved a high accuracy (94%). Patients divided according to the prognostic parameter differ in overall survival and time to first treatment (p < 0.0001, HR  = 2.300/5.970, 95% CI: 1.587–3.450/4.621–15.86). Our approach provides a reliable alternative method to prognosis assessment viaIGHVmutational status analysis. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

40. Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group

Author

Smolej, Lukas, primary, Brychtova, Yvona, additional, Doubek, Michael, additional, Cmunt, Eduard, additional, Spacek, Martin, additional, Belada, David, additional, Motyckova, Monika, additional, Zygulova, Irena, additional, Adamova, Dagmar, additional, Prochazka, Vit, additional, Simkovic, Martin, additional, Klaskova, Katerina, additional, and Kozak, Tomas, additional

Published
2014
Full Text
View/download PDF

41. Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial

Author

Greil, Richard, primary, Obrtlikova, Petra, additional, Smolej, Lukas, additional, Kozak, Tomas, additional, Steurer, Michael, additional, Andel, Johannes, additional, Thaler, Josef, additional, Mikuskova, Eva, additional, Gercheva, Liana, additional, Nösslinger, Thomas, additional, Ladicka, Miriam, additional, Girschikofsky, Michael, additional, Hrubiško, Mikuláš, additional, Jäger, Ulrich, additional, Fridrik, Michael A., additional, Pecherstorfer, Martin, additional, Kralikova, Eva, additional, Burcoveanu, Cristina, additional, Goranov, Stefcho, additional, Jurkovikova, Jana, additional, Petzer, Andreas L., additional, Mihaylov, Georgi G., additional, Raynov, Julian, additional, Oexle, Horst, additional, Zabernigg, August, additional, Flochova, Emilia, additional, Palasthy, Stanislav, additional, Melchardt, Thomas, additional, Mayer, Jiri, additional, and Egle, Alexander, additional

Published
2014
Full Text
View/download PDF

42. Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results

Author

van Oers, Marinus H.J., primary, Kuliczkowski, Kazimierz, additional, Smolej, Lukas, additional, Petrini, Mario, additional, Offner, Fritz, additional, Gorsicki, Sebastian, additional, Levin, Mark-David, additional, Gupta, Ira, additional, Phillips, Jennifer, additional, Williams, Vanessa, additional, Lisby, Steen, additional, and Geisler, Christian, additional

Published
2014
Full Text
View/download PDF

44. Ofatumumab Added To Dexamethasone In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia. Results From a Phase II Study Of The Czech Leukemia Study Group For Life

Author

Doubek, Michael, primary, Brychtova, Yvona, additional, Panovska, Anna, additional, Trizuljak, Jakub, additional, Sebejova, Ludmila, additional, Stehlikova, Olga, additional, Chovancova, Jana, additional, Malcikova, Jitka, additional, Smardova, Jana, additional, Plevova, Karla, additional, Volfova, Pavlina, additional, Trbusek, Martin, additional, Mraz, Marek, additional, Majercakova, Denisa, additional, Obrtlikova, Petra, additional, Karban, Josef, additional, Smolej, Lukas, additional, Lindtnerova, Michaela, additional, Oltova, Alexandra, additional, Jelinkova, Eva, additional, Pospisilova, Sarka, additional, and Mayer, Jiri, additional

Published
2013
Full Text
View/download PDF

45. A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study

Author

Moreno, Carol, primary, Montillo, Marco, additional, Panayiotis, Panayiotidis, additional, Bloor, Adrian, additional, Dupuis, Jehan, additional, Schuh, Anna, additional, Norin, Stefan, additional, Geisler, Christian H, additional, Hillmen, Peter, additional, Doubek, Michael, additional, Obrtlikova, Petra, additional, Laurenti, Luca, additional, Stilgenbauer, Stephan, additional, Smolej, Lukas, additional, Ghia, Paolo, additional, Cymbalista, Florence, additional, Jaeger, Ulrich, additional, Stavroyianni, Niki, additional, Carrington, Patrick, additional, Zouabi, Hamadi, additional, Leblond, Veronique, additional, Gomez, Juan Carlos, additional, Marasca, Roberto, additional, Musuraca, Gerardo, additional, Rigacci, Luigi, additional, Farina, Lucia, additional, Paolini, Rossella, additional, Pospisilova, Sarka, additional, Kimby, Eva, additional, Bradley, Colm, additional, and Montserrat, Emili, additional

Published
2013
Full Text
View/download PDF

47. The Fate of Chronic Lymphocytic Leukemia Patients After Failure of Fludarabine, Cyclophosphamide, and Rituximab Regimen

Author

Panovska, Anna, primary, Lysák, Daniel, additional, Smolej, Lukas, additional, Brychtova, Yvona, additional, Simkovic, Martin, additional, Motyckova, Monika, additional, Lindtnerova, Michaela, additional, Trbusek, Martin, additional, Malcikova, Jitka, additional, Pospisilova, Sarka, additional, Mayer, Jiri, additional, and Doubek, Michael, additional

Published
2012
Full Text
View/download PDF

49. Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL.

Author

Österborg, Anders, primary, Dyer, Martin J. S., additional, Mayer, Jiri, additional, Hess, Georg, additional, Hillmen, Peter, additional, Schetelig, Johannes, additional, Schuh, Anna, additional, Smolej, Lukas, additional, Beck, Christian, additional, Dreyfus, Brigitte, additional, Hellman, Andrzej, additional, Kozlowski, Piotr, additional, Pfreundschuh, Michael, additional, Rizzi, Rita, additional, Spacek, Martin, additional, Chan, Geoffrey, additional, Gupta, Ira, additional, Phillips, Jennifer, additional, Lisby, Steen, additional, and Wierda, William G., additional

Published
2012
Full Text
View/download PDF

50. Five-Color Multiplex Real-Time PCR Technology to Detect Over 75 Recurrent Chromosomal Abnormalities in Acute Myeloid Leukemia; Benefits for Minimal Residual Disease Detection

Author

Plachy, Radek, primary, Zejskova, Lenka, additional, Cmejla, Radek, additional, Hardekopf, David Warren, additional, Jancuskova, Tereza, additional, Krutilkova, Lucie, additional, Karas, Michal, additional, Koza, Vladimir, additional, Vydra, Jan, additional, Zak, Pavel, additional, Smolej, Lukas, additional, and Pekova, Sona, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results